泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获得FDA孤儿药资格认定

Core Viewpoint - Zai Lab's investigational product ZG006 has received Orphan-drug Designation from the FDA for the treatment of neuroendocrine cancer [1] Group 1 - The product ZG006 is an injectable formulation [1] - The Orphan-drug Designation is a significant regulatory milestone that may facilitate the development and commercialization of ZG006 [1]